Yeni Nesil Antiandrojenler
Özet
Prostat kanseri tedavisinde, hastalığın androjen bağımlı doğası nedeniyle androjen baskılayıcı tedaviler (ADT) temel taşı oluşturmaktadır. Son yıllarda geliştirilen yeni nesil antiandrojenler, özellikle metastatik kastrasyon duyarlı (mKDPK) ve rezistan (mKRPK) ile non-metastatik kastrasyon dirençli (nmKRPK) prostat kanseri hastalarında sağkalım sürelerini anlamlı derecede uzatmıştır. Bu ajanlardan abirateron asetat, CYP17 enzimini inhibe ederek testis, adrenal bez ve tümör dokusundaki androjen biyosentezini engelleyip serum testosteron seviyelerini düşürür; ancak mineralokortikoid artışına bağlı yan etkileri önlemek için prednizon ile kombine edilir. Bir diğer önemli ajan olan enzalutamid, androjen reseptör sinyal yolağındaki reseptöre bağlanma, nükleer translokasyon ve DNA'ya bağlanma gibi çoklu basamakları hedefleyen nonsteroidal bir antiandrojendir ve klinik çalışmalarda belirgin genel sağkalım katkısı sağlamıştır. Benzer etki mekanizmasına sahip apalutamid, enzalutamide kıyasla daha az merkezi sinir sistemi toksisitesi gösterirken; darolutamid ise nmKRPK hastalarında metastazsız sağkalım ve sekonder sonlanım noktalarında yüksek etkinlik ve güvenilirlik sunmaktadır. Bu yeni nesil tedaviler, prostat kanserinin farklı evrelerinde sağkalım avantajı ve yönetilebilir yan etki profilleriyle standart bakımın bir parçası haline gelmiştir.
In the treatment of prostate cancer, androgen deprivation therapies (ADT) constitute the cornerstone due to the androgen-dependent nature of the disease. In recent years, newly developed next-generation antiandrogens have significantly prolonged survival times, particularly in patients with metastatic castration-sensitive (mCSPC), metastatic castration-resistant (mCRPC), and non-metastatic castration-resistant prostate cancer (nmCRPC). Among these agents, abiraterone acetate inhibits the CYP17 enzyme to block androgen biosynthesis in testicular, adrenal, and tumor tissues, thereby lowering serum testosterone levels; however, it must be combined with prednisone to prevent side effects related to mineralocorticoid increase. Another critical agent, enzalutamide, is a nonsteroidal antiandrogen that targets multiple steps in the androgen receptor signaling pathway, including receptor binding, nuclear translocation, and DNA binding, demonstrating a distinct overall survival benefit in clinical trials. Sharing a similar mechanism of action, apalutamid exhibits less central nervous system toxicity compared to enzalutamide, whereas darolutamide offers high efficacy and safety in nmCRPC patients by significantly improving metastasis-free survival and secondary endpoints. These next-generation therapies have become a fundamental part of standard care across various stages of prostate cancer, offering substantial survival advantages and manageable side effect profiles.
Referanslar
Siegel RL, Miller KD, Fuchs HE, et al: Cancer statistics, 2022. 72:7-33, 2022
Tan G, Xuan Z, Li Z, et al: The efficacy and safety of abiraterone acetate in patients with high-risk prostate cancer: a meta-analysis based on six randomized control trials. 2020 9:1691-1699, 2020
Moreira RB, Debiasi M, Francini E, et al: Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. 8, 2017
Mottet N, van den Bergh RCN, Briers E, et al: EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 79:243-262, 2021
Fizazi K, Tran N, Fein L, et al: Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20:686-700, 2019
Clarke NW, Ali A, Ingleby FC, et al: Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 30:1992-2003, 2019
Fizazi K, Foulon S, Carles J, et al: Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2× 2 factorial design. 399:1695-1707, 2022
Fizazi K, Scher HI, Molina A, et al: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology 13:983-992, 2012
Ryan CJ, Smith MR, Fizazi K, et al: Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology 16:152-160, 2015
Mostaghel EA: Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res 6:39-51, 2014
Rice MA, Malhotra SV, Stoyanova T: Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Front Oncol 9:801, 2019
Nadal R, Taplin ME, Bellmunt J: Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. Future Oncol 10:351-62, 2014
Beer TM, Armstrong AJ, Rathkopf DE, et al: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424-33, 2014
Armstrong AJ, Lin P, Tombal B, et al: Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol 78:347-357, 2020
Tombal B, Saad F, Penson D, et al: Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 20:556-569, 2019
Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al: ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 37:2974-2986, 2019
Shore ND, Chowdhury S, Villers A, et al: Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. 17:153-163, 2016
Slovin S, Clark W, Carles J, et al: Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure: the UPWARD study. 4:702-706, 2018
Small EJ, Saad F, Chowdhury S, et al: SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC), American Society of Clinical Oncology, 2018
Fizazi K, Shore ND, Tammela T, et al: Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC), American Society of Clinical Oncology, 2020
